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Abstract
Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare genetic disorder for which no cure exists. The disease
is characterized by premature aging and inevitable death in adolescence due to cardiovascular complications. Most
HGPS patients carry a heterozygous de novo LMNA c.1824C > T mutation, which provokes the expression of a dominant-
negative mutant protein called progerin. Therapies proven effective in HGPS-like mouse models have yielded only
modest benefit in HGPS clinical trials. To overcome the gap between HGPS mouse models and patients, we
have generated by CRISPR-Cas9 gene editing the first large animal model for HGPS, a knockin heterozygous LMNA
c.1824C > T Yucatan minipig. Like HGPS patients, HGPS minipigs endogenously co-express progerin and normal lamin
A/C, and exhibit severe growth retardation, lipodystrophy, skin and bone alterations, cardiovascular disease, and die
around puberty. Remarkably, the HGPS minipigs recapitulate critical cardiovascular alterations seen in patients, such as
left ventricular diastolic dysfunction, altered cardiac electrical activity, and loss of vascular smooth muscle cells. Our
analysis also revealed reduced myocardial perfusion due to microvascular damage and myocardial interstitial fibrosis,
previously undescribed readouts potentially useful for monitoring disease progression in patients. The HGPS minipigs
provide an appropriate preclinical model in which to test human-size interventional devices and optimize candidate
therapies before advancing to clinical trials, thus accelerating the development of effective applications for HGPS
patients.
Introduction
Hutchinson-Gilford progeria syndrome (HGPS) is an
extremely rare disorder (prevalence of 1 in 20 million;
https://www.progeriaresearch.org/) characterized by pre-
mature aging and death during adolescence1,2. “Classical”
HGPS is caused by a de novo heterozygous mutation in
the LMNA gene (encoding A-type lamins), with more
than 90% of patients carrying a c.1824C > T (pG608G)
point mutation3,4. This mutation activates usage of an
alternative 5′ splice donor site in exon 11 that results in
deletion of 150 nucleotides from LMNA mRNA and the
synthesis of a truncated protein called progerin. This
aberrant protein accumulates in the nuclear envelope due
to irreversible farnesylation and causes severe alterations
in multiple cellular functions1,2 (Supplementary Fig. S1).
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HGPS patients appear normal at birth and typically do
not manifest signs of disease until around 1–2 years of
age, when they begin to exhibit failure to thrive and
develop symptoms reminiscent of physiological aging,
including alopecia, lipodystrophy, pigmented spots and
skin wrinkling with sclerodermia, and bone-skeletal dys-
plasia. One of the main alterations in HGPS is cardio-
vascular disease (CVD), featuring atherosclerosis, vascular
stiffening and calcification, electrocardiographic (ECG)
alterations, and left ventricular (LV) diastolic dysfunc-
tion5–9. To date, there is no effective therapy or cure for
HGPS, and patients die at an average age of 14.6 years
predominantly due to CVD complications10.
The extreme rarity of HGPS makes the organization of
any clinical trial a huge challenge where the inevitable
limitation of a small patient cohort adds to the difficulty of
deciding which therapies effective in HGPS-like mice
should be tested in patients. Available HGPS mouse
models either ectopically express progerin, lack or over-
express A-type lamin isoforms, or accumulate farnesy-
lated prelamin A (Supplementary Fig. S1)2,11. Despite
their limitations, HGPS-like mice have been the gold-
standard preclinical model and have led to clinical trials
testing the ability of repurposed drugs to reduce progerin
farnesylation12. Targeting progerin farnesylation resulted
in a mild benefit in body weight, bone, and vascular
alterations in a subset of HGPS patients and was asso-
ciated with lower mortality rate after 2.2 years of follow-
up; however, the estimated increase in life expectancy is
only 1.6 years10,13–15, highlighting the limitations in
translating results of preclinical mouse studies to HGPS
patients.
New gene editing methodologies are enabling transla-
tional biomedicine to bridge the gap between mice and
humans through the use of pig models16–20. Pigs share
strong genetic, anatomical, and physiological similarities
with humans, and they are increasingly used for pre-
clinical testing of preventive or therapeutic drugs and
other interventions, toxicity tests, studies of human dis-
ease processes, and functional genomics21,22. Particularly
relevant to HGPS is the close similarity of the pig and
human cardiovascular systems; pig and human hearts
have a similar size and, together with primates, the pig
model provides the closest match to human coronary
vasculature, blood flow, hemodynamics, and myocardial
contractility. Indeed, the growth of the heart and vascular
system in pigs from birth to 4 months of age is analogous
to the growth of the same system in humans into the mid-
teens23. Lipoprotein profiles and metabolism are also very
similar in pigs and humans.
Yucatan minipigs are sociable, reach puberty at around
4–6 months of age, have a life expectancy of ~10 years,
and can grow to ~80kg24. Yucatan minipigs are therefore
manageable throughout their life, while being large
enough for study or intervention with the same technol-
ogy used for human diagnosis. To overcome the gap
between progeroid mouse models and HGPS patients,
here we describe the generation and characterization of
the first pig model of “classical” HGPS, a knockin Yucatan
minipig harboring the heterozygous LMNA c.1824C > T
mutation. Like patients, HGPS minipigs endogenously co-
express progerin and A-type lamins and recapitulate all
the main symptoms of human HGPS, including CVD and
its death-related complications.
Results
Generation of HGPS Yucatan minipigs
HGPS knockin Yucatan minipigs carrying a hetero-
zygous LMNA c.1824C > T mutation were generated using
CRISPR (clustered regularly interspaced short palindromic
repeats)-Cas9 (CRISPR-associated protein 9) gene edit-
ing25,26 in male Yucatan minipig skin fibroblasts, followed
by somatic cell nuclear transfer (SCNT) by handmade
cloning to enucleated oocytes from Large White sows27
(Supplementary Fig. 2a). Our genetic engineering strategy
omitted insertion of antibiotic or fluorescent selection
cassettes in the genomic DNA while retaining the intact
PAM sequence for Cas9 guidance to avoid the generation
of potential splicing sites in addition to the one resulting
from introduction of the LMNA c.1824C > T mutation.
Three single guide RNAs (sgRNAs) were constructed to
target exon 11 in the porcine LMNA gene. sgRNA1 was
selected for subsequent gene editing experiments due to
its consistency when tested in an in vitro validation
assay28. Information on the different molecular tools is
available in Supplementary Tables S1–2. Skin primary
fibroblasts from a newborn male Yucatan minipig were
co-transfected with sgRNA1, a Cas9 plasmid construct, an
enhanced green fluorescent protein (EGFP) reporter
plasmid, and a donor DNA construct including the
c.1824C > T mutation flanked by a left and a right
homology arm (see Fig. 1a for donor DNA template
design and Supplementary Table S1 for the primers used
for its generation). To enrich for transfected cells, EGFP-
expressing cells were isolated by fluorescence-activated
cell sorting, seeded on 96-well plates, and expanded as
single-cell colonies. Allele-specific PCR was performed on
lysates from all surviving cell clones to select c.1824C > T-
positive clones. Subsequent sequencing identified only
one clone harboring the desired heterozygous LMNA
c.1824C > T mutation without unwanted insertions,
deletions, or base changes in the region involved in
homologous recombination (Fig. 1b). Moreover, this
HGPS cell clone showed no evidence of off-target Cas9
effects or random integration of the vectors used (sgRNA,
Cas9, EGFP-N3, and the donor molecule backbone). The
clone was therefore used as the nuclear donor for SCNT
into enucleated oocytes from Large White sows27. Viable
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Fig. 1 Knockin heterozygous LMNA c.1824C > T Yucatan minipigs exhibit HGPS-like external phenotype, growth retardation, and
premature death. a Genetic engineering procedure for generating Hutchinson-Gilford progeria syndrome (HGPS) knockin Yucatan minipig
fibroblasts by CRISPR/Cas9-mediated homologous recombination. The area of hybridization for sgRNA1 in genomic DNA is indicated by a yellow
arrowhead, the area of recombination between genomic DNA and donor DNA template is indicated by green lines, and the single C > T base
mutation in the donor DNA template is indicated by a red T in exon 11. LHA and RHA respectively indicate the left and right homology arms
surrounding the C > T mutation (not drawn to scale). For an overview of the whole method to generate HGPS minipigs and its efficiency see
Supplementary Fig. S2. For detailed information of molecular tools see Supplementary Table S1 and 2. b Genomic LMNA exon 11 sequence of wild-
type (WT) minipig fibroblasts and the generated heterozygous HGPS knockin fibroblast clone. Note that WT cells are homozygous for the C
nucleotide in position c.1824 (blue arrowhead), and HGPS cells harbor both the WT C allele and the mutant T allele (red arrowhead). c Representative
photographs showing the normal appearance of HGPS minipigs at birth and the severe premature-aging external phenotype at 5.5–6 months of age.
Note that pictures were not taken at the same distance. See also Supplementary Fig. S3 and Movies S1-5. d HGPS Yucatan minipigs experience
difficulty to thrive. The graph shows body weight/age curves (n= 6 WT; n= 10 HGPS). e HGPS minipigs die prematurely. Green dots in the Kaplan-
Meier survival curve are censored data (1 HGPS minipig died during anesthesia induction in preparation for imaging tests and another was
euthanized due to humane end-point criteria)
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reconstructed embryos were transferred to three surro-
gate Large White sows29. A total of 19 cloned male piglets
were obtained (5 stillborn and 14 liveborn), of which
10 survived the postnatal period (Supplementary Fig. 2b).
All obtained piglets were genotyped as heterozygous for
LMNA c.1824C > T.
Growth retardation, external symptoms, and premature
death
The HGPS piglets had a normal appearance and size at
birth (Fig. 1c, left; Supplementary Movie S1) and until
~2.5 months of age (Supplementary Movie S2). From
then on, the HGPS minipigs progressively developed an
angular and narrow face, dry and taut skin, occasional
difficulty in standing up due to joint rigidity, and failure
to thrive (Fig. 1d). From ~4 to 4.5 months of age, body
weight gain was severely impaired (Fig. 1d). Moreover,
from this age, all the HGPS minipigs showed frailty and
symptoms reminiscent of human HGPS, with intensity
varying between individuals. These symptoms included
prominent eyes and short eyelids with frequent
corneal ulcerations, wrinkled and taut skin with patchy
punctate pigmentation, large areas of alopecia and/or
areas with hardened/thickened hair, a sculpted nose,
thin lips, prominent teeth, a below-normal body
mass index accompanied by subcutaneous fat loss and
prominent bones, and thin limbs with severe joint
stiffness (Fig. 1c, right; Supplementary Fig. S3, and
Movies S3-5).
None of the HGPS minipigs survived beyond the age of
6.6 months (survival ranging from 137 to 200 days; mean
life span 177.3 ± 21.4 days) (Fig. 1e). One HGPS minipig
was euthanized at 182 days of age due to humane end-
point criteria, and another pig died at 141 days of age
during anesthesia induction in preparation for in vivo
cardiac function tests. Compared with age-matched wild-
type (WT) controls, ~5- to 5.5-month-old HGPS minipigs
showed no major differences in hematology and coagu-
lation parameters (not shown). Likewise, serum analysis
revealed no alterations in total cholesterol, free choles-
terol, or triglycerides between WT and HGPS minipigs;
however, HGPS minipigs had above-normal serum low-
density lipoprotein and below-normal serum high-density
lipoprotein (Supplementary Table S3), similar to HGPS
patients6.
Progerin expression
Primers for PCR-based detection of progerin mRNA in
porcine tissues were based on the human progerin mRNA
sequence (NCBI accession number NM_001282626.1)
(Fig. 2a and Materials and methods). All HGPS minipig
tissues tested were positive for a 482-bp band corre-
sponding to an amplicon spanning a 150-nucleotide
deletion caused by the LMNA 1824C > T mutation; this
band was absent in WT tissues (Fig. 2b). Sequencing of
this amplicon revealed 94.9% homology between the 3′
end of progerin mRNA (exon 10–12) in HGPS minipigs
and HGPS patients, with only a few mismatches corre-
sponding to single-nucleotide polymorphisms between
the two species. Remarkably, the predicted amino-acid
sequence corresponding to the HGPS pig 3′ mRNA
revealed conservation of the critical C-terminal CSIM
motif, which is irreversibly farnesylated and carboxy-
methylated in human progerin (Fig. 2c). We also inves-
tigated progerin protein expression in heart and aorta,
which are severely affected in HGPS. Western blot
demonstrated the presence of progerin in HGPS tissues
but not in WT tissues, with an electrophoretic mobility
between those of lamin A and lamin C (Fig. 2d). These
results demonstrate that heterozygous LMNA c.1824C >
T Yucatan minipigs, like HGPS patients, endogenously
co-express progerin mRNA and protein in all tissues
tested.
Myocardial microvascular dysfunction and fibrosis
We performed cardiac magnetic resonance imaging
(MRI) in 4.3- to 5.4-month-old HGPS and WT Yucatan
minipigs. T1 and T2 mapping and overall LV extracellular
volume fraction showed no significant differences
between WT and HGPS minipigs. However, qualitative
analysis of late gadolinium contrast enhancement images
revealed patchy gadolinium deposition in the anterior LV
wall and septal regions in three out of eight HGPS
minipigs (Fig. 3a). Cardiac MRI (cMRI)-quantified myo-
cardial perfusion30 was significantly lower in HGPS
minipigs (Fig. 3b), indicating overt LV microvascular
damage.
We next performed hematoxilyn & eosin (H&E) and
Masson trichrome (MT) staining in transverse heart
sections (between the atrium and apex) obtained after
necropsy. Compared with controls, the LV of the HGPS
minipigs had double amount of medium and large cor-
onary arteries (medium, 65–250 μm diameter; large, >250
μm diameter, including the medial layer). Moreover, in
five out of eight HGPS minipigs, ~21% of these vessels
showed signs of atherosclerotic disease including medial
degeneration and intimal hypertrophy (Supplementary
Fig. S4a, b). The amounts of medium/large coronaries in
the septum were similar in WT and HGPS minipigs, but
more than 21% of these vessels were degenerated in three
out of eight HGPS minipigs (occlusion ranging from 26 to
83% of coronaries in different HGPS minipigs) (Supple-
mentary Fig. S4a–b). In addition, MT staining in medium/
large LV and septal coronaries revealed significantly
higher collagen deposition in both the medial and
adventitial layers of arterioles in HGPS minipigs (Fig. 3c),
accompanied by a trend toward adventitial hypertrophy in
six out of eight HGPS minipigs (Fig. 3c, ratio adventitia/
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media). We also observed occasional vessel occlusion in
HGPS minipigs in the subpleural arteries, aorta, and vasa
vasorum (not shown).
Loss of smooth muscle cells is a hallmark of human and
mouse HGPS vessels31–35. Consistent with these findings,
immunofluorescence studies demonstrated significantly
Fig. 2 Progerin expression in Hutchinson-Gilford progeria syndrome (HGPS) minipigs. a Design of primers for PCR amplification of progerin
mRNA. F forward primer, R reverse primer (which spans from progerin exon 12 to the 3′ end of exon 11 across the in-frame 150-nucleotide deletion
produced by the alternative splicing caused by the LMNA c.1824C > T mutation). b Representative agarose gels showing PCR detection of progerin
mRNA in wild-type (WT) and HGPS minipig tissues (each lane corresponds to a different pig). Skin fibroblasts from HGPS patients and healthy controls
were used as positive and negative controls, respectively. First lane, DNA ladder. c Comparison of the C-terminal amino-acid sequences of human
progerin and HGPS minipig progerin, which was predicted with ExPASy software from the DNA sequence of the gel-purified 482-bp PCR product
specific to HGPS pigs (cf. b). d Representative immunoblots for lamin A/C and progerin protein in WT and HGPS minipig heart and aorta (heart: 60 µg
protein/lane, aorta: 30 µg protein/lane; each lane corresponds to a different pig). Fibroblasts from WT and HGPS mice (LmnaG609G) were used as
progerin expression-negative and -positive controls, respectively. GADPH was used as loading control
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Fig. 3 (See legend on next page.)
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lower α-smooth muscle actin immunoreactivity in the
medial layer of medium/large LV and septal coronaries in
HGPS minipigs (Fig. 3d and Supplementary Fig. S4c).
Although H&E staining did not reveal gross myocardial
tissue abnormalities, image quantification after MT
deconvolution demonstrated significantly higher inter-
stitial fibrosis in the septum of HGPS minipigs than in
similar locations in WT minipig hearts (mean % of six
vessel-free areas of 470 μm2 each) (Fig. 3e). Together,
these histological results confirm the in vivo MRI findings,
demonstrating increased myocardial fibrosis and reduced
perfusion (cf. Fig. 3a, b).
Systolic and diastolic myocardial dysfunction
We examined cardiac function in 4.3- to 5.4-month-old
HGPS and WT Yucatan minipigs using gold-standard
clinical non-invasive techniques, including cardiac MRI
and transthoracic echocardiography. MRI examination
revealed no significant between-genotype differences in
LV size (measured as LV end-diastolic volume: LVEDV)
or LV mass (Supplementary Fig. S5a–b). However, the
HGPS minipigs displayed overt LV systolic dysfunction,
with a significantly lower LV ejection fraction (LVEF)
than controls (Fig. 4a). Echocardiography revealed dia-
stolic dysfunction in HGPS minipigs, evidenced by several
mitral inflow Doppler parameters, including a trend to
lower E′ wave, and higher E/E′ ratios (Supplementary
Fig. S5c-d) and a significantly shorter early mitral decel-
eration time (DT) (Fig. 4b). In agreement with the Dop-
pler findings, the HGPS minipigs had significantly
enlarged left atria (Fig. 4c). Moreover, two out of eight
HGPS minipigs showed signs of mild mitral valve
degeneration with accompanying mitral regurgitation. In
contrast, the aortic, pulmonary, and tricuspid valves
showed no alterations in HGPS minipigs. Overall, cardiac
phenotyping by advanced multimodality imaging showed
signs of mixed systolic and diastolic heart dysfunction in
the HGPS minipigs.
ECG alterations and severe pre-mortem cardiac conduction
abnormalities
We next recorded 12-lead ECG tracings (Fig. 5a, b). The
HGPS minipigs had a significantly lower heart rate and a
wider QRS complex than WT controls. Conversely, cor-
rected QT intervals were shorter in the HGPS minipigs,
with no significant changes in the PR interval.
We also performed confocal microscopy studies in heart
to investigate the localization of connexin 43 (Cnx43) and
N-Cadherin (N-Cadh); these proteins are normally
expressed in the intercalated disk between adjacent car-
diomyocytes and are essential for proper mechanical and
electrical coupling and propagation of the electrical
impulse36. The cardiomyocyte membranes of HGPS
minipigs showed aberrant Cnx43 localization associated
with below-normal N-Cadh/Cnx43 co-localization
(Fig. 5c).
Cardiac electrical activity was monitored continuously
in vivo by placing implanted loop recorders (ILR) sub-
cutaneously in five WT and four HGPS minipigs (Fig. 6a).
Single-lead ECG recordings were obtained at the moment
of death in three out of four HGPS minipigs. The WT
minipigs did not show abnormal single-lead ECG para-
meters in the ILR (Fig. 6b). In contrast, three HGPS
minipigs showed an advanced third degree atrio-
ventricular block (total interruption of atrio-ventricular
conduction) at the moment of death (Fig. 6c, d). In one
HGPS minipig, complete atrio-ventricular block was
preceded by a short-duration polymorphic ventricular
tachycardia (Fig. 6c). Moreover, in another HGPS minipig
the atrio-ventricular block was immediately preceded by
ST-segment elevation, which was not present 29 h before
death (Fig. 6d). This observation suggests a coronary
(see figure on previous page)
Fig. 3 Heart microvascular dysfunction and fibrosis in Hutchinson-Gilford progeria syndrome (HGPS) minipigs. a Left ventricular (LV) fibrosis
in HGPS minipigs revealed by delayed gadolinium enhancement magnetic resonance imaging (MRI). Representative images are shown. Red
arrowheads indicate the area of contrast deposition. b LV microvascular damage in HGPS minipigs determined by cardiac MRI-determined absolute
quantitative perfusion after gadolinium administration (n= 6 WT and n= 7 HGPS minipigs, 4.3–5.5 months old). The images show representative
examples of LV flow with perfusion ranging from 50 (red) to 200 (yellow) ml/min/100 g. Arrowheads indicate the non-perfused area. c Collagen
deposition in LV and septal coronary arteries of WT and HGPS hearts. Images show representative Masson trichrome (MT) staining of heart cross
sections, revealing increased collagen deposition (green/blue staining) in HGPS hearts. Left and center graphs: mean percentage collagen content in
medial and adventitial layers of arterioles >65 μm in diameter, quantified by image deconvolution (area analyzed, 170 mm2 in LV and 120mm2 in
septum). Right graph: adventitial hyperthrophy quantified as the ratio of adventitial to medial perimeter (11–27 arterioles of mean diameter >50 μm
per minipig in LV or septum). d Smooth muscle cell loss in the medial layer of LV and septum arterioles in HGPS minipigs. Representative
immunofluorescence images show staining for α-smooth muscle actin (SMA) in red, CD31 (endothelial cell marker) in green, and nuclei in blue. The
graph shows mean percentage SMA signals in the medial layer of 12–41 arterioles per minipig in LV or septum. See also Supplementary Fig. S4.
e Representative images of MT staining in heart cross sections, showing myocardial fibrosis in HGPS minipigs. Black arrows indicate areas of intense
MT staining. Images were deconvoluted to quantify mean percentage myocardial fibrosis in vessel-free myocardial areas (seven areas in LV and six
areas in septum; 470 μm2 each region analyzed)
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ischemic event potentially related to microvascular dys-
function and vascular fibrosis (cf. Fig. 3).
Other alterations in HGPS minipigs
MRI analysis of brain showed no cerebrovascular dis-
ease in the HGPS minipigs. None of the images indicated
any localization with hyper-intense regions on FLAIR
images or hypo-intense regions on T1-weighted images,
which would be indicative of localized regions of stroke.
Vascular microbleeds were not detected, as indicated by
the lack of localized signal decay in T2*-weighted images
(data not shown).
Gross histological examination of kidney, testicle,
spleen, liver, and lung revealed pathological features only
Fig. 4 Systolic and diastolic dysfunction in Hutchinson-Gilford progeria syndrome (HGPS) minipigs. Cardiac magnetic resonance imaging
(MRI) and echocardiography analysis of HGPS minipigs (n= 7–8) and wild-type (WT) minipigs (n= 5–6) of a similar age (~4.3–5.5 months) revealed
enlarged left atria (LA) and increased left ventricular (LV) filling pressures, as well as systolic and diastolic LV dysfunction in HGPS minipigs. a MRI
measurements of LV ejection fraction (LVEF). Representative four chamber long axis views are shown on the left. b Echocardiographic measurements
of mitral early wave deceleration time (shown in yellow numbers in the representative images on the left). c Echocardiographic measurements of LA
size (shown in yellow numbers in the representative images on the left. See also unaffected systolic and diastolic parameters in HGPS minipigs in
Supplementary Fig. S5
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in the kidneys and testicles of HGPS minipigs. In
the case of kidney, 88% of the HGPS minipigs showed
dilation of cortical tubules and different degrees of
glomerulosclerosis (Supplementary Fig. S6a). Testicles in
the HGPS minipigs showed signs of delayed maturation,
including a low number of interstitial Leydig cells and a
Fig. 5 Electrocardiographic (ECG) alterations and aberrant connexin 43 (Cnx43) localization in the hearts of Hutchinson-Gilford progeria
syndrome (HGPS) minipigs. a Representative ECG traces recorded in wild-type (WT) and HGPS minipigs. b HGPS minipigs show bradycardia and
QRS complex prolongation on ECG. For each parameter, a set of 10 beats per animal was analyzed and the mean was represented. c Cnx43 is
mislocalized in the plasma membrane of HGPS cardiomyocytes. Representative immunofluorescence images of heart tissue show staining for Cnx43
(green), N-Cadh (red), and nuclei (blue). The graph shows the percentage of N-Cadh/Cnx43 co-localization based on the mean of three 236 µm2 areas
per heart tissue sample
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near absence of mature spermatids (Supplementary
Fig. S6b).
It proved impossible to establish an HGPS minipig
colony through conventional breeding because disease
symptoms in the male HGPS minipigs became severe
during the period corresponding to pubertal development
(from ~4 to 6 months of age) and none of the pigs sur-
vived to a post-pubertal age. As an alternative strategy, we
collected and froze epididymal sperm from three
necropsied HGPS minipig testicles and attempted surgical
intrauterine insemination of two gilts treated with hor-
mones to induce ovulation. One gilt received 300 × 106
spermatozoids with 78.6% viability, 45% motility, and 62%
acrosomal damage, and the other received 87.5 × 106
spermatozoids with 46.4% viability, 15% motility, and 36%
acrosomal damage. Ultrasonography revealed an absence
of pregnancy 28 days after insemination in both gilts.
Discussion
The generation of a large animal model for HGPS
addresses the need for a more translational preclinical
model of this devastating disease. Like patients carrying
the heterozygous LMNA c.1824C > T mutation, the HGPS
minipigs co-express endogenous progerin, lamin A and C,
thus circumventing the limitation of HGPS-like mouse
models lacking or overexpressing A-type lamin iso-
forms2,11. Progerin expression in the HGPS minipigs
induced all major progeroid symptoms that, like in
patients, are variable in severity along the time-course of
disease, increase with age and culminate in early death.
Fig. 6 Severe pre-mortem cardiac conduction abnormalities in Hutchinson-Gilford progeria syndrome (HGPS) minipigs. a An implantable
loop recorder used for continuous electrocardiography (ECG) monitoring after subcutaneous implantation in wild-type (WT) and HGPS minipigs.
b Representative single-lead ECG trace from a WT minipig. c ECG trace from a HGPS minipig, showing a wide QRS complex and short-duration
polymorphic ventricular tachycardia before complete atrio-ventricular block at the moment of death. d ECG trace from a HGPS minipig, showing ST-
segment elevation immediately before complete atrio-ventricular block at the moment of death. Red arrows in b–d indicate the P waves on the
surface ECG; blue asterisks indicate the QRS complex. Traces correspond to a standard sweep speed of 25 mm/s and standard amplitude calibration
of 10 mm/mV
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We focused our studies on CVD, which is considered the
main cause of death in HGPS.
LV diastolic dysfunction was the most frequent echo-
cardiographic abnormality in a cohort of 27 HGPS
patients, with prevalence higher in the oldest patients7. LV
systolic dysfunction and valve disease were infrequently
seen in the first decade of life but became more prevalent
in the second decade7. HGPS minipigs develop both
systolic and diastolic dysfunction (including left atrial
enlargement suggesting elevated LV filling pressure),
which are common underlying causes of heart failure.
Also consistent with reports in HGPS patients6,7,32,37–40,
we found signs of mild mitral valve degeneration
accompanied by mild mitral regurgitation in two of eight
HGPS minipigs.
Prakash et al. reported normal ECG parameters in 25 of
27 HGPS patients7. However, ECG alterations were more
prevalent (47%) in our previous study of 15 HGPS patients
and 13 sex- and aged-matched healthy volunteers8. This
apparent discrepancy may reflect differences in the median
age at evaluation in the two cohorts (median age of 5.6
[2–17] years7 versus 11.5 [2–19] years8), with the older
cohort predicted to have a greater burden of ECG altera-
tions9. Notably, the HGPS minipigs exhibited significant
ECG abnormalities at advanced disease stages, in parti-
cular longer QRS complex duration and significant bra-
dycardia, in agreement with ECG alterations reported in
progeroid mice at advanced disease stages8. The HGPS
minipigs also showed Cnx43 mislocalization in the heart as
an underlying cellular alteration related to ECG abnorm-
alities, consistent with previous findings in HGPS patients
and progeroid mice8. We further investigated cardiac
electrical activity through continuous in vivo recordings,
which revealed pre-mortem advanced atrio-ventricular
conduction block in three out of four HGPS minipigs.
Moreover, the short-duration polymorphic ventricular
tachycardia observed in one HGPS minipig before com-
plete atrio-ventricular block (likely related to severe bra-
dycardia) is in agreement with our previous findings
demonstrating premature ventricular complexes in pro-
geroid mice during sequential ECG examination8. Another
HGPS minipig had overt ST elevation at the moment of
death, suggesting that myocardial ischemia may have
contributed to the atrio-ventricular block. Consistent with
this, our in vivo cardiac MRI studies identified reduced
myocardial perfusion and interstitial fibrosis, both con-
tributing to the diastolic LV dysfunction phenotype in the
HGPS minipigs. These MRI findings are confirmed by the
histopathological studies revealing a significant proportion
of degenerated medium-to-large coronaries and above-
normal collagen deposition in cardiac arterioles and
myocardial tissue. The defective myocardial perfusion and
interstitial fibrosis are previously unidentified cardiovas-
cular alterations in genetically diagnosed HGPS patients
that deserve attention when monitoring disease progres-
sion in patients and can be used as in vivo readouts in
clinical trials. Our HGPS minipig model can guide future
research into the natural history of CVD in HGPS and aid
in the important task of elucidating primary molecular and
cellular mechanisms of progerin-induced damage. These
knockin minipigs should also help to identify early bio-
markers of disease progression and responses to therapies.
The course of disease in the HGPS minipigs correlates
well with the timing of disease onset, progression, and
death in patients, with both species manifesting symptoms
a certain period after birth and dying around puberty.
With a mean life span of just ∼6 months, our HGPS
minipig model is ideal for preclinical studies, because it
offers a wide window for therapeutic interventions to
prevent the appearance of symptoms or revert the phe-
notype, while also permitting longevity studies over a
relatively short period. This favorable timing will enor-
mously facilitate the execution of future preclinical tests.
Indeed, this HGPS minipig model can provide an appro-
priate filter for drug-based strategies with proven effi-
ciency in HGPS-like mice12 before moving them forward
to clinical trials. The expectation is that any preclinical
tests in HGPS minipigs will yield highly translatable
results regarding drug regimes, administration routes,
bioavailability, pharmacokinetics, efficacy, and acute
toxicity. Likewise, these knockin minipigs should help in
the development and optimization of cell-based therapies
and systemic or tissue-specific gene therapy. Notably, the
c.1824C > T mutation in the pig LMNA gene provokes
progerin expression, suggesting that HGPS minipigs may
be useful for testing therapies targeting aberrant LMNA
exon 11–12 splicing, such as morpholino-oligonucleo-
tides, which showed efficacy in progeroid mice33 but await
testing in a large animal model.
The human-like size of the HGPS minipig model is
another key advantage that allowed the use of the same
MRI, echography, ECG, and telemetry devices used in
hospitals for human diagnosis. Due to dentition and
mandibular problems, anesthesia is considered a risky
procedure in HGPS patients. The HGPS minipigs reca-
pitulate these dental and facial bone alterations, and due
to the narrow airway in these animals, standard intubation
for anesthesia was substituted in some cases by ventilation
with canine laryngeal masks. Any interventional trial in
HGPS minipigs involving anesthesia will therefore face
similar challenges to those encountered with HGPS
patients, and will thus produce invaluable translational
results. For all these reasons, we expect this progeroid
minipig model to have a strong and positive impact on
HGPS by expediting the development of effective thera-
pies for HGPS patients.
The difficulty encountered in establishing a HGPS
minipig colony either by mating HGPS boars with WT
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sows or by surgery-assisted fertilization of sows with
sperm obtained from HGPS minipigs was unsurprising
given the lack of fitness and delayed pubertal development
among the male HGPS minipigs. Although we were able
to cryopreserve and freeze small amounts of sperm from
HGPS necropsied testicles, attempts to surgically inse-
minate two hormone-treated gilts were unsuccessful.
Therefore, the generation of new HGPS minipigs for
future preclinical trials will require either in vitro fertili-
zation or recloning using our heterozygous LMNA 1824C
> T Yucatan minipig fibroblast clone or fibroblasts iso-
lated from HGPS minipigs. While disadvantageous from
the perspective of colony generation, the lack of repro-
ductive fitness is a further example of the recapitulation of
disease symptoms seen in patients, who experience
delayed or absent pubertal development. For example, a
12-year-old HGPS female patient and a 17-year-old HGPS
male patient were classified as Tanner developmental
stage II (first appearance of pubic hair and breast buds,
and a slight enlargement of penis and testicles, respec-
tively)6. Additionally, a group of female HGPS patients
aged over 12 years and who declared having experienced
menarche remained between the Tanner I and II pubertal
stages even 2 years after their menarche41. To our
knowledge, there are no reports of the potential viability
of gametes from HGPS patients. Although the dose of A-
type lamins can affect spermatogenesis in rodents42, A-
type lamins were not detected in human spermatids or
mature spermetazoa43. Consequently, no progerin-
induced damage would be expected in mature HGPS
spermatozoids. Recently, it was reported that mouse
LmnaG609G/G609G oocytes are meiotically competent and
can be fertilized by WT spermatozoids and that
LmnaG609G/G609G sperm, although not abundant, is motile
and able to fertilize WT oocytes44. The same authors
propose that the sub-fertility in LmnaG609G/G609G mice
may simply be a consequence of the lack of physical fit-
ness. This idea is supported by the physical condition of
the HGPS minipigs and the low numbers of interstitial
Leydig cells and mature spermatids, indicating delayed
pubertal development. These findings may reflect a failure
of the minipigs to achieve the necessary weight or fat
threshold to trigger sexual maturation.
A potential limitation of our study is that we only
included male HGPS minipigs because all the cloned
animals were derived from genetically modified fibroblasts
obtained from a male Yucatan minipig. However, no
gender-specific alterations have been reported in HGPS
patients, and we expect future preclinical results gener-
ated in our HGPS minipig model to be equally transla-
table to male and female patients.
We believe that our heterozygous LMNA c.1824C > T
Yucatan minipig model is a bona fide and necessary
bridge between HPGS mouse models and patients.
These knockin minipigs provide an appropriate large
animal model in which to test human-size interventional
devices (like stents or pacemakers), and standardize
surgical models or medical protocols using the same
methodologies utilized with patients. Importantly,
HGPS minipigs will facilitate the optimization of drug
regimens escalated from small- to large-body-size
mammals, and will accelerate the unraveling of poten-
tial counteracting toxicities in combined new therapies,
or side effects in challenging future cures. This model
will therefore facilitate decision-making about which
therapeutic strategies should advance to clinical trials
and potentially expedite the development of effective
therapeutic applications for HGPS patients. Moreover,
as progerin is expressed at low levels in tissues from
aged non-HGPS individuals (reviewed in ref. 2), we
believe that research in this HGPS minipig model may
also shed light into the complex mechanisms underlying
physiological aging.
Materials and methods
The data, analytic methods, and study materials will be
made available to other researchers for purposes of
reproducing the results or replicating the procedure
(available at the authors’ laboratories). Supplementary
Fig. S2a shows an overview of the method for generating
the HGPS minipigs. Detailed protocols of all the steps
followed for generating HGPS minipigs and assisted
reproduction, and expression studies are in Supplemen-
tary Information.
Study approval
All animal procedures at Aarhus University (AU) were
approved by the Danish Animal Experiments Inspectorate
(licence no. 2014-15-0201-00434). Experimental proce-
dures at the Centro Nacional de Investigaciones Cardio-
vasculares (CNIC), Universidad de Murcia, and the
Spanish National Institute for Agricultural and Food
Research and Technology conform to EU Directive 2010/
63EU and Recommendation 2007/526/EC, enforced in
Spanish law under Real Decreto 53/2013. Animal proto-
cols were approved by the respective local ethics com-
mittees. Animal work at the CNIC was approved by the
Comunidad Autónoma de Madrid (PROEX #313/16). The
cloned HGPS animals were generated at AU and housed
in a specific pathogen-free facility under standard condi-
tions. At ~3.5 months of age, animals were transported to
Agropardal S.L. (Cuenca, Spain), a farm dedicated exclu-
sively to the breeding of experimental pigs. Phenotypic
characterization of minipigs was conducted at the CNIC’s
animal facility. Surgical intrauterine insemination of gilts
was carried out at the Universidad de Murcia. All minipigs
were uncastrated Yucatan males except for two WT
minipigs that were castrated and excluded in weight and
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survival studies. We used non-littermate WT controls
because it was not possible to cross the male HGPS
minipigs with WT gilts.
Anesthesia
Anesthesia was administered to all Yucatan minipigs
before proceeding with non-invasive procedures and
implantation of a telemetry monitor. Anesthesia
was induced by intramuscular injection of ketamine
(20 mg) followed by continuous intravenous infusion of
ketamine (2 mg/kg/h), xylazine (0.2 mg/kg/h), and mid-
azolam (0.2 mg/kg/h) throughout the protocol.
Echocardiography
Diastolic function patterns were studied with a Com-
mercial scanner (iE33, Philips Healthcare) and the stan-
dard techniques45,46. Likewise, valve function was
analyzed according to European Society of Cardiology
guidelines45. Ultrasound images were analyzed with Qlab
R 9.1 (Philips Medical Systems) by two expert observers
blinded to genotype. Pulsed-wave Doppler imaging was
used to determine mitral valve inflow velocity during early
(E) and late (A) diastole, E/A velocity ratio, mitral E
velocity DT, septal early (E′) diastolic myocardial velocity,
and E/E′ ratio. In addition, left atrium antero-posterior
dimensions were obtained and normalized to body surface
area using the modified Brody’s formula47,48. Images were
analyzed by two researchers blinded to genotype.
Cardiac MRI
CMRI studies were performed in a 3 Tesla Philips
Achieva Tx whole-body scanner (Philips Healthcare)
equipped with a 32-element phased-array cardiac coil.
The imaging protocol included anatomical and functional
assessment using a segmented cine steady-state free-pre-
cession (SSFP) sequence with spatial resolution of 1.8 ×
1.8 mm, end-diastolic acquisition, thickness 6 mm with no
gap, and 30 fully acquired cardiac phases. Segmented cine
SSFP was performed to acquire 11–13 contiguous short-
axis slices covering the heart from the base to the apex in
order to evaluate global and regional LV motion. Multi-
parametric tissue characterization was performed using
T2 mapping and pre- (native) and post-contrast T1
mapping techniques and absolute quantitative perfusion.
T2 mapping data were acquired using a previously vali-
dated T2-GraSE sequence with eight equally spaced echo-
times ranging from 6.7 to 53.7 ms49. T1 mapping images
were captured using a 5(3)3 MOLLI scheme with a single-
shot balanced acquisition (TR/TE/Flip, 2.1 ms/1.05 ms/
35°) and a spatial resolution of 1.5 × 1.8 × 8.0 mm3. Tissue
characterization parameters were acquired from a single
mid-ventricular slice in short-axis orientation. Micro-
vascular status was studied with a previously reported
methodology to assess absolute quantitative perfusion
using a dual saturation recovery sequence30. Macro areas
of increased extracellular space (a fibrosis surrogate) were
assessed by delayed gadolinium enhancement (10–15 min
after intravenous administration of 0.20 mmol gadobutrol
contrast agent per kg body weight) using a T1-weighted
three-dimensional inversion recovery sequence with an
adjusted inversion time to null the healthy myocardium
and an isotropic resolution of 1.5 × 1.5 × 1.5 mm3. CMR
images were analyzed using dedicated software (MR
Extended Work Space 2.6, Philips Healthcare, and QMass
MR 7.6, Medis) by two observers experienced in CMR
analysis who were blinded to genotype. LVEF, LV
volumes, and LV mass were calculated by tracing endo-
cardial/epicardial borders during end-systole and end-
diastole in short-axis slices. Mapping analyses were per-
formed with a region of interest in a mid-apical LV short-
axis slice. All volumes and masses were normalized to
body surface area using the modified Brody’s formula47,48.
Images were analyzed by two researchers blinded to
genotype.
Electrocardiography
The 12-lead ECG recordings were obtained before
imaging studies using the same anesthesia period. ECG
recordings were acquired at 1 kHz for at least 5 min
(LabSystem-Pro recording system, Boston Scientific). PR,
QRS, and QT intervals were measured using manual
calipers at a 200 mm/s sweep speed. QRS complex dura-
tion was measured as the time from the lead showing the
earliest deflection (positive or negative) to the lead with
the latest offset of the QRS complex50. QT intervals were
corrected with the Bazzet formula. A set of 10 beats per
animal was analyzed and the mean value of each ECG
parameter was assigned to the animal. Two researchers
blinded to the genotype performed the analysis.
Implantable loop recorder placement
ILR (Reveal Linq, Medtronic) were placed sub-
cutaneously in four HGPS and five WT Yucatan minipigs
under local anesthesia with lidocaine 1% (5ml, 1 mg/ml
vials). The device was placed subcutaneously on the left
side of the sternum to ensure accurate QRS complex
recordings.
Hematology and metabolic profile
Blood samples were analyzed in an ADVIA 2120i
hematology system (Siemens). Serum samples were ana-
lyzed in a Dimension RxL Max analyzer (Siemens).
Statistics
Statistical significance was assessed by unpaired two-
tailed Student’s t-test using GraphPad Prism software,
except for the % fibrosis in LV and septal myocardium in
Fig. 3e, for which an unpaired one-tailed Student’s t-test
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was used. A log-rank (Mantel-Cox) test was used for the
Kaplan-Meier survival curve. Differences were considered
significant at p < 0.05.
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